Johnson & Johnson: Shockwave Medical Further Validates Utility of Intravascular Lithotripsy in Lower Limb Lesions in Late-Breaking Presentation at VIVA 2024
November 04, 2024
November 04, 2024
NEW BRUNSWICK, New Jersey, Nov. 4 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
DISRUPT BTK II, a global post-market study, finds favorable 30-day outcomes for peripheral IVL in the most challenging calcified lesions, including patients with CLTI
* * *
LAS VEGAS - Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global leader in the field of circulatory restoration, announced the 30-day primary end . . .
* * *
DISRUPT BTK II, a global post-market study, finds favorable 30-day outcomes for peripheral IVL in the most challenging calcified lesions, including patients with CLTI
* * *
LAS VEGAS - Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global leader in the field of circulatory restoration, announced the 30-day primary end . . .